Your browser is no longer supported. Please, upgrade your browser.
ASRT Assertio Therapeutics, Inc. daily Stock Chart
ASRT [NASD]
Assertio Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.97 Insider Own0.60% Shs Outstand70.94M Perf Week13.23%
Market Cap85.62M Forward P/E6.58 EPS next Y0.15 Insider Trans-2.95% Shs Float80.16M Perf Month9.48%
Income-161.70M PEG- EPS next Q-0.03 Inst Own66.70% Short Float2.54% Perf Quarter-8.65%
Sales192.50M P/S0.44 EPS this Y-634.30% Inst Trans-17.92% Short Ratio1.54 Perf Half Y27.58%
Book/sh1.18 P/B0.84 EPS next Y36.36% ROA-27.90% Target Price1.35 Perf Year-68.68%
Cash/sh- P/C- EPS next 5Y25.00% ROE-110.00% 52W Range0.55 - 3.63 Perf YTD-21.07%
Dividend- P/FCF2.33 EPS past 5Y-28.50% ROI-39.80% 52W High-72.82% Beta2.16
Dividend %- Quick Ratio1.50 Sales past 5Y-10.10% Gross Margin95.70% 52W Low79.38% ATR0.11
Employees125 Current Ratio1.50 Sales Q/Q-63.90% Oper. Margin-55.90% RSI (14)65.94 Volatility13.98% 12.50%
OptionableYes Debt/Eq0.69 EPS Q/Q360.70% Profit Margin-84.00% Rel Volume1.29 Prev Close0.96
ShortableYes LT Debt/Eq0.00 EarningsMay 11 BMO Payout- Avg Volume1.32M Price0.99
Recom2.00 SMA2017.88% SMA5024.56% SMA200-5.46% Volume1,710,463 Change3.22%
Nov-30-18Downgrade Mizuho Buy → Neutral
May-22-20 07:24AM  STOCKHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Assertio Therapeutics, Inc. - ASRT PR Newswire -6.19%
May-21-20 06:30AM  Maple Leaf Foods Receives TSX Approval To Proceed With Normal Course Issuer Bid PR Newswire
May-20-20 06:20PM  Maple Leaf Foods Management Information Circular Now Available PR Newswire +13.01%
08:48AM  Assertio Completed Merger with Zyla Life Sciences PR Newswire
May-17-20 08:09AM  One Analyst's Earnings Estimates For Assertio Therapeutics, Inc. (NASDAQ:ASRT) Are Surging Higher Simply Wall St.
May-11-20 10:35AM  Assertio (ASRT) Beats Q1 Earnings and Revenue Estimates Zacks +8.98%
08:17AM  Recap: Assertio Therapeutics Q1 Earnings Benzinga
08:00AM  Assertio Therapeutics Announces First-Quarter 2020 Results GlobeNewswire
May-08-20 10:41PM  SHAREHOLDER ALERT: Halper Sadeh LLP Investigates The Merger Of Assertio Therapeutics, Inc.; Investors Are Encouraged To Contact The Firm PR Newswire
10:10PM  ASSERTIO MERGER INVESTIGATION: Halper Sadeh LLP Announces Investigation Into Whether The Merger Of Assertio Therapeutics, Inc. Is Fair To Shareholders; Investors Are Encouraged To Contact The Firm ACCESSWIRE
07:02PM  SHAREHOLDER ALERT: WeissLaw LLP Investigates Assertio Therapeutics, Inc. PR Newswire
May-06-20 12:30PM  Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-30-20 12:00PM  All You Need to Know About Assertio (ASRT) Rating Upgrade to Buy Zacks
Apr-20-20 05:08PM  Assertio Therapeutics Announces its Virtual 2020 Annual Meeting on May 19, 2020, and Mailing of its Joint Proxy Statement/Prospectus GlobeNewswire
Apr-08-20 04:05PM  Assertio Therapeutics Announces Completion and Final Results of the Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes due 2021 and 5.00% Senior Convertible Notes due 2024 GlobeNewswire
Apr-02-20 06:24AM  Does Assertio Therapeutics, Inc. (NASDAQ:ASRT) Have A Particularly Volatile Share Price? Simply Wall St.
Mar-17-20 11:41AM  Wayne-based drug company enters into $17.5M merger deal American City Business Journals
10:15AM  Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of These Companies WLTW, TTPH, ASRT, MEET GlobeNewswire
Mar-16-20 06:45PM  Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products GlobeNewswire -6.25%
Mar-11-20 01:01AM  Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024 GlobeNewswire +25.67%
Mar-09-20 05:55PM  Assertio (ASRT) Reports Q4 Loss, Tops Revenue Estimates Zacks -6.14%
04:02PM  Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2019 Financial Results GlobeNewswire
02:30AM  Assertio Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-08-20 04:14PM  The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues Benzinga
Mar-02-20 05:30PM  Assertio Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results After the Close of Markets on Monday, March 9, 2020 GlobeNewswire
Feb-26-20 12:30PM  Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-24-20 10:33AM  Assertio (ASRT) to Report Q4 Earnings: What's in Store? Zacks -10.69%
Feb-19-20 08:00AM  Assertio Therapeutics Announces Repurchase of Approximately $188.0 Million of its Outstanding Convertible Debt GlobeNewswire +6.98%
Feb-17-20 06:00AM  Did Changing Sentiment Drive Assertio Therapeutics's (NASDAQ:ASRT) Share Price Down A Painful 93%? Simply Wall St.
Feb-14-20 08:23AM  The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering Benzinga
Feb-13-20 04:05PM  Assertio Therapeutics Announces Closing of Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million GlobeNewswire
Feb-07-20 07:32AM  The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns Benzinga +46.15%
Feb-06-20 04:01PM  Assertio Therapeutics Announces Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million GlobeNewswire
Feb-04-20 05:45PM  Assertio (ASRT) Gains But Lags Market: What You Should Know Zacks
Jan-29-20 05:45PM  Assertio (ASRT) Dips More Than Broader Markets: What You Should Know Zacks
Jan-22-20 11:30AM  Is ASSERTIO THERAPEUTICS, INC (ASRT) Outperforming Other Medical Stocks This Year? Zacks
Jan-15-20 05:45PM  Assertio (ASRT) Stock Sinks As Market Gains: What You Should Know Zacks
Jan-13-20 11:40AM  ASRT or PCRX: Which Is the Better Value Stock Right Now? Zacks
07:50AM  Assertio Therapeutics Announces Closing of Gralise® Sale to Alvogen and Expects Full-Year 2019 Neurology Franchise Net Sales Above Upper End of Prior Guidance GlobeNewswire
Jan-09-20 05:45PM  Assertio (ASRT) Stock Sinks As Market Gains: What You Should Know Zacks
Jan-08-20 10:18AM  Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up Zacks -6.09%
Jan-07-20 09:51AM  Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA Zacks +6.48%
09:17AM  Catalyst Gives Preliminary Firdapse Estimates & Other Updates Zacks
Dec-27-19 11:40AM  ASRT vs. PCRX: Which Stock Is the Better Value Option? Zacks
Dec-23-19 12:00PM  Assertio (ASRT) Upgraded to Strong Buy: What Does It Mean for the Stock? Zacks
Dec-19-19 06:40AM  Need To Know: Assertio Therapeutics, Inc. (NASDAQ:ASRT) Insiders Have Been Buying Shares Simply Wall St.
Dec-13-19 03:07PM  Hedge Funds Are Crazy About Assertio Therapeutics, Inc. (ASRT) Insider Monkey
08:39AM  Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M Zacks
Dec-12-19 07:50AM  Assertio Therapeutics Announces Sale of Gralise® for Total Transaction Value of $127.5 Million GlobeNewswire +56.65%
Dec-10-19 11:40AM  ASRT vs. PCRX: Which Stock Should Value Investors Buy Now? Zacks +7.99%
Nov-26-19 02:29PM  Assertio Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-13-19 12:58PM  Assertio Therapeutics to Present at the 2019 Stifel Healthcare Conference GlobeNewswire +11.25%
Nov-07-19 11:26AM  PDL BioPharma (PDLI) Q3 Earnings Beat, LENSAR Drives Sales Zacks
Nov-06-19 07:45PM  Assertio (ASRT) Surpasses Q3 Earnings Estimates Zacks -12.08%
04:05PM  Assertio Therapeutics Announces Third-Quarter 2019 Results GlobeNewswire
Nov-04-19 06:05AM  How Much Did Assertio Therapeutics, Inc.'s (NASDAQ:ASRT) CEO Pocket Last Year? Simply Wall St.
Oct-30-19 06:35PM  Ceridian HCM Holding, BJ's Wholesale Club Holdings Set to Join S&P MidCap 400; Oceaneering International, Covetrus to Join S&P SmallCap 600 PR Newswire
10:34AM  Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-23-19 09:05AM  Assertio Therapeutics to Report Third-Quarter 2019 Financial Results After the Close of Markets on Wednesday, November 6, 2019 GlobeNewswire
Oct-22-19 07:51AM  The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug Benzinga
Oct-21-19 09:05AM  Assertio Therapeutics Provides Regulatory Update on Long-Acting Cosyntropin GlobeNewswire -28.13%
Oct-13-19 04:33PM  The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings Benzinga
Oct-05-19 09:54AM  How Does Assertio Therapeutics, Inc. (NASDAQ:ASRT) Affect Your Portfolio Volatility? Simply Wall St.
Sep-30-19 12:35PM  Assertio Therapeutics Announces Appointment of Dr. David Wheadon to its Board of Directors GlobeNewswire
Sep-26-19 08:00AM  Assertio Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-24-19 05:38PM  Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes CNW Group
Sep-20-19 09:40AM  ASRT vs. ZTS: Which Stock Is the Better Value Option? Zacks
Sep-09-19 09:50AM  Top Ranked Value Stocks to Buy for September 9th Zacks
Sep-05-19 11:05AM  If You Had Bought Assertio Therapeutics (NASDAQ:ASRT) Stock Three Years Ago, You'd Be Sitting On A 94% Loss, Today Simply Wall St.
Sep-04-19 09:30AM  ASRT vs. ZTS: Which Stock Should Value Investors Buy Now? Zacks
Aug-20-19 08:00AM  Assertio Therapeutics to Present at the 17th Annual Morgan Stanley Global Healthcare Conference GlobeNewswire -16.87%
07:59AM  Assertio Therapeutics Enters Oversold Territory Zacks
Aug-19-19 09:30AM  ASRT vs. PCRX: Which Stock Is the Better Value Option? Zacks
Aug-12-19 09:15PM  Assertio Therapeutics Inc (ASRT) Director, President and CEO Arthur J Higgins Bought $77,000 of ... GuruFocus.com
Aug-09-19 09:28AM  Assertio Therapeutics Announces Exchange Offer of $200 Million of its Currently Outstanding 2.50% Convertible Notes Due 2021 GlobeNewswire -45.91%
Aug-08-19 11:24PM  Assertio Therapeutics, Inc (ASRT) Q2 2019 Earnings Call Transcript Motley Fool +5.64%
Aug-07-19 07:35PM  Assertio (ASRT) Q2 Earnings Beat Estimates Zacks
04:02PM  Assertio Therapeutics Announces Strong Second-Quarter 2019 Results GlobeNewswire
Aug-06-19 03:22PM  Is Assertio Therapeutics (NASDAQ:ASRT) A Risky Investment? Simply Wall St.
Jul-31-19 10:36AM  Assertio (ASRT) Earnings Expected to Grow: Should You Buy? Zacks
Jul-26-19 09:30AM  ASRT or AMRX: Which Is the Better Value Stock Right Now? Zacks
Jul-17-19 04:05PM  Assertio Therapeutics to Report Second Quarter 2019 Financial Results After The Close of Markets on Wednesday, August 7, 2019 GlobeNewswire -8.38%
Jul-01-19 08:39AM  La Jolla (LJPC) Secures Positive CHMP Opinion for Giapreza Zacks
Jun-23-19 08:53PM  Heres What Hedge Funds Think About Assertio Therapeutics, Inc. (ASRT) Insider Monkey
Jun-22-19 10:37AM  Have Insiders Been Buying Assertio Therapeutics, Inc. (NASDAQ:ASRT) Shares? Simply Wall St.
Jun-13-19 09:50AM  Savara Plunges on Failure of Late-Stage Study on Molgradex Zacks
May-20-19 10:28AM  ASSERTIO THERAPEUTICS Enters Oversold Territory Zacks
May-14-19 09:30AM  Is ASSERTIO THERAPEUTICS, INC (ASRT) Stock Outpacing Its Medical Peers This Year? Zacks
May-09-19 11:24AM  Assertio Therapeutics, Inc (ASRT) Q1 2019 Earnings Call Transcript Motley Fool
May-08-19 05:25PM  Assertio (ASRT) Tops Q1 Earnings and Revenue Estimates Zacks
04:17PM  Assertio: 1Q Earnings Snapshot Associated Press
04:02PM  Assertio Therapeutics Announces First-Quarter 2019 Financial Results GlobeNewswire
May-06-19 11:54AM  Assertio Therapeutics (ASRT) to Post Q1 Earnings: What's Up? Zacks
May-01-19 10:33AM  Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-24-19 04:46PM  Assertio Therapeutics to Report First Quarter 2019 Financial Results After The Close of Markets on Wednesday, May 8, 2019 GlobeNewswire
Apr-23-19 08:22AM  What Assertio Therapeutics, Inc.'s (NASDAQ:ASRT) ROE Can Tell Us Simply Wall St.
Apr-16-19 07:17PM  Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65% Zacks
Apr-01-19 09:00AM  Assertio Therapeutics Announces Appointment of Jay Galeota to Board of Directors GlobeNewswire
Mar-28-19 06:12PM  Magellan Health nears board deal with hedge fund Starboard Value - sources Reuters +6.62%
01:51PM  Assertio Therapeutics Announces Favorable NUCYNTA® Patent Ruling GlobeNewswire
Assertio Therapeutics, Inc., a specialty pharmaceutical company, provides medicines in neurology, orphan, and specialty areas in the United States. The company offers Gralise (gabapentin), a once daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; and Zipsor (diclofenac potassium liquid filled capsules), a non-steroidal anti-inflammatory drug for treating mild to moderate acute pain. It also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to require daily, around-the-clock, and long term opioid treatment, including neuropathic pain related to diabetic peripheral neuropathy in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, the company offers long-acting cosyntropin, an alcohol-free formulation of synthetic adrenocorticotropic hormone. Assertio Therapeutics, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc. The company was formerly known as Depomed Inc. and changed its name to Assertio Therapeutics, Inc. in August 2018. Assertio Therapeutics, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DAWES KAREN ADirectorMay 08Sale0.7915,83412,53184,589May 11 08:23 PM
Bukofzer StanSVP, Chf Scitfc & Tech OfficerApr 02Option Exercise0.0025,370070,349Apr 03 06:50 PM
Galeota James JRDirectorMar 30Option Exercise0.0012,492012,492Mar 31 07:32 PM
Mason Heather LDirectorFeb 18Option Exercise0.0014,394014,394Feb 19 05:00 PM
Peisert Daniel A.SVP and CFOFeb 12Option Exercise0.0027,5880112,753Feb 12 06:41 PM
Bukofzer StanSVP, Chf Scitfc & Tech OfficerFeb 12Option Exercise0.0027,588054,524Feb 12 06:40 PM
HIGGINS ARTHUR JDirector, President and CEOFeb 12Option Exercise0.0097,4120275,747Feb 12 06:41 PM
HIGGINS ARTHUR JDirector, President and CEOFeb 06Option Exercise0.0062,3990199,925Feb 06 05:49 PM
Peisert Daniel A.SVP and CFOFeb 06Option Exercise0.006,700087,483Feb 06 05:49 PM
HIGGINS ARTHUR JDirector, President and CEODec 01Option Exercise0.0034,8600147,739Dec 02 05:20 PM
Peisert Daniel A.SVP and CFODec 01Option Exercise0.008,359083,232Dec 02 05:20 PM
HIGGINS ARTHUR JDirector, President and CEONov 12Buy0.7325,00018,250112,879Nov 12 04:36 PM
STAPLE PETER DDirectorNov 11Buy0.7113,9009,91113,900Nov 12 04:36 PM
Peisert Daniel A.SVP and CFONov 11Buy0.7310,0007,25974,873Nov 12 04:36 PM